| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Gene Is an Oncogene in Human Ovarian and Colon Tumors1
Surgical Oncology Research Laboratory [A. J. P., C. L., E. V., S. P. R., R. J. S. T., W. A. P.] and Victorian Breast Cancer Research Consortium Cancer Genetics Laboratory [I. G. C.], Peter MacCallum Cancer Institute, Melbourne, Victoria 3002, and Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Melbourne, Victoria 3050 [R. H. W.], Australia
Phosphatidylinositol 3'-kinases (PI3ks) are a family of lipid kinases that play a crucial role in a wide range of important cellular processes associated with malignant behavior including cell growth, migration, and survival. We have used single-strand conformational polymorphism/heteroduplex analysis to demonstrate the presence of somatic mutations in the gene for the p85
regulatory subunit of PI3k (PIK3R1) in primary human colon and ovarian tumors and cancer cell lines. All of the mutations lead to deletions in the inter-SH2 region of the molecule proximal to the serine608 autoregulatory site. Expression of a mutant protein with a 23 amino acid deletion leads to constitutive activation of PI3k providing the first direct evidence that p85
is a new oncogene involved in human tumorigenesis.
This article has been cited by other articles:
![]() |
T.-V. Do, L. A. Kubba, M. Antenos, A. W. Rademaker, C. D. Sturgis, and T. K. Woodruff The Role of Activin A and Akt/GSK Signaling in Ovarian Tumor Biology Endocrinology, August 1, 2008; 149(8): 3809 - 3816. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Chamberlain, T. Chan, J. C. Oberg, A. D. Hawrysh, K. M. James, A. Saxena, J. Xiang, and D. H. Anderson Disrupted RabGAP Function of the p85 Subunit of Phosphatidylinositol 3-Kinase Results in Cell Transformation J. Biol. Chem., June 6, 2008; 283(23): 15861 - 15868. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Baltgalvis, F. G. Berger, M. M. O. Pena, J. M. Davis, and J. A. Carson Effect of exercise on biological pathways in ApcMin/+ mouse intestinal polyps J Appl Physiol, April 1, 2008; 104(4): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jhawer, S. Goel, A. J. Wilson, C. Montagna, Y.-H. Ling, D.-S. Byun, S. Nasser, D. Arango, J. Shin, L. Klampfer, et al. PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab Cancer Res., March 15, 2008; 68(6): 1953 - 1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Amornphimoltham, V. Patel, K. Leelahavanichkul, R. T. Abraham, and J. S. Gutkind A Retroinhibition Approach Reveals a Tumor Cell-Autonomous Response to Rapamycin in Head and Neck Cancer Cancer Res., February 15, 2008; 68(4): 1144 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, S. J. Plummer, C. L. Thompson, T. C. Tucker, and G. Casey Association between Phosphatidylinositol 3-Kinase Regulatory Subunit p85{alpha} Met326Ile Genetic Polymorphism and Colon Cancer Risk Clin. Cancer Res., February 1, 2008; 14(3): 633 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations Science, December 14, 2007; 318(5857): 1744 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shao, M.K. Washington, R. Saxena, and H. Sheng Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin Carcinogenesis, December 1, 2007; 28(12): 2476 - 2483. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chaudhuri, S. Orsulic, and B. T. Ashok Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 334 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer. Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Campbell, W. A. Phillips, and D. Y.H. Choong Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers. Clin. Cancer Res., June 15, 2006; 12(12): 3713 - 3715. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells Cancer Res., December 1, 2005; 65(23): 10992 - 11000. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Maffucci, E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, S. Iacobelli, et al. Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects Cancer Res., September 15, 2005; 65(18): 8339 - 8349. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Rascoe, X. Cao, J. C. Daniel, S. D. Miller, and W. R. Smythe Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 393 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Shekar, H. Wu, Z. Fu, S.-C. Yip, Nagajyothi, S. M. Cahill, M. E. Girvin, and J. M. Backer Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit J. Biol. Chem., July 29, 2005; 280(30): 27850 - 27855. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikenoue, F. Kanai, Y. Hikiba, T. Obata, Y. Tanaka, J. Imamura, M. Ohta, A. Jazag, B. Guleng, K. Tateishi, et al. Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer Cancer Res., June 1, 2005; 65(11): 4562 - 4567. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xing and S. Orsulic A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance PNAS, May 10, 2005; 102(19): 6936 - 6941. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Levine, F. Bogomolniy, C. J. Yee, A. Lash, R. R. Barakat, P. I. Borgen, and J. Boyd Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers Clin. Cancer Res., April 15, 2005; 11(8): 2875 - 2878. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shin, J. Edl, S. Biswas, P. C. Lin, R. Mernaugh, and C. L. Arteaga Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies Cancer Res., April 1, 2005; 65(7): 2815 - 2824. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kang, A. G. Bader, and P. K. Vogt Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic PNAS, January 18, 2005; 102(3): 802 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Chou, L.-H. Wei, M.-L. Kuo, Y.-J. Huang, K.-P. Lai, C.-A. Chen, and C.-Y. Hsieh Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-{kappa}B pathway by lysophosphatidic acid, an ovarian cancer-activating factor Carcinogenesis, January 1, 2005; 26(1): 45 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Azriel-Tamir, H. Sharir, B. Schwartz, and M. Hershfinkel Extracellular Zinc Triggers ERK-dependent Activation of Na+/H+ Exchange in Colonocytes Mediated by the Zinc-sensing Receptor J. Biol. Chem., December 10, 2004; 279(50): 51804 - 51816. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Campbell, S. E. Russell, D. Y. H. Choong, K. G. Montgomery, M. L. Ciavarella, C. S. F. Hooi, B. E. Cristiano, R. B. Pearson, and W. A. Phillips Mutation of the PIK3CA Gene in Ovarian and Breast Cancer Cancer Res., November 1, 2004; 64(21): 7678 - 7681. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Skinner, J. Z. Zheng, J. Fang, F. Agani, and B.-H. Jiang Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1{alpha}, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling J. Biol. Chem., October 29, 2004; 279(44): 45643 - 45651. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, L. M. Gronning, P. O. Anderson, S. Li, K. Edvardsen, J. Johnston, D. Kioussis, P. R. Shepherd, and P. Wang Insulin Induces SOCS-6 Expression and Its Binding to the p85 Monomer of Phosphoinositide 3-Kinase, Resulting in Improvement in Glucose Metabolism J. Biol. Chem., August 13, 2004; 279(33): 34107 - 34114. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Spaner Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sansal and W. R. Sellers The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway J. Clin. Oncol., July 15, 2004; 22(14): 2954 - 2963. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Shin, T. N. Fredrickson, J. W. Hartley, T. Suzuki, K. Agaki, and H. C. Morse III High-Throughput Retroviral Tagging for Identification of Genes Involved in Initiation and Progression of Mouse Splenic Marginal Zone Lymphomas Cancer Res., July 1, 2004; 64(13): 4419 - 4427. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Foukas, C. A. Beeton, J. Jensen, W. A. Phillips, and P. R. Shepherd Regulation of Phosphoinositide 3-Kinase by Its Intrinsic Serine Kinase Activity In Vivo Mol. Cell. Biol., February 1, 2004; 24(3): 966 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Matei, D. D. Chang, and M.-H. Jeng Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor {alpha} and Akt Inactivation Clin. Cancer Res., January 15, 2004; 10(2): 681 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sawyer, J. Sturge, D. C. Bennett, M. J. O'Hare, W. E. Allen, J. Bain, G. E. Jones, and B. Vanhaesebroeck Regulation of Breast Cancer Cell Chemotaxis by the Phosphoinositide 3-Kinase p110{delta} Cancer Res., April 1, 2003; 63(7): 1667 - 1675. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Arboleda, J. F. Lyons, F. F. Kabbinavar, M. R. Bray, B. E. Snow, R. Ayala, M. Danino, B. Y. Karlan, and D. J. Slamon Overexpression of AKT2/Protein Kinase B{beta} Leads to Up-Regulation of {beta}1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells Cancer Res., January 1, 2003; 63(1): 196 - 206. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |